Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal
Ficlatuzumab Combo Enters Phase III
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.